Physician profile
Carsten Robert Hamann
NPI 1538546957
$364,367.18
in general payments reported to CMS, 2019-2025
40 companies · $228K in 2025
The $228K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $1,271 · 2023: $23K · 2024: $111K · 2025: $228K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $253K · Consulting Fee: $75K · Travel and Lodging: $19K · Food and Beverage: $15K · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $252,961.80 |
| Consulting Fee | $75,244.60 |
| Travel and Lodging | $18,939.77 |
| Food and Beverage | $15,186.36 |
| Education | $485.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $159,960.49 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $128,330.22 | 2021-2025 | |
| Pfizer INC. | $49,086.03 | 2022-2025 | |
| Galderma Laboratories, L.P. | $10,066.70 | 2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $3,903.82 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Leo Pharma As | $3,212.23 | 2025 | Anzupgo |
| Arcutis Biotherapeutics, INC. | $3,196.95 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,119.61 | 2021-2025 | |
| Janssen Biotech, INC. | $1,060.14 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Dermavant Sciences, INC. | $656.24 | 2023-2024 | Vtama |
| Lilly USA, LLC | $647.74 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $447.19 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $424.53 | 2021-2025 | Ilumya |
| Incyte Corporation | $418.82 | 2023-2025 | Opzelura |
| Ucb, INC. | $398.51 | 2023-2025 | Bimzelx |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,338,598.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carsten Hamann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.